General Mills, Inc. ( GIS ) has failed to meet expectations per the company’s last quarterly report, and investors have (arguably rightly) been pulling out. However, I believe we’ve reached the bottom or are at least approaching it. Given this, IMarkets rise and fall, booms come and go, and the world keeps ticking. Ultimately, I believe observing megatrends, as difficult as they can be to spot, let alone fully comprehend, can yield insights into the advance of human society, which in turn could pave the way ...

Key Takeaways Cardinal Health saw GLP-1 drugs add about six percentage points to segment revenue growth in Q2 FY26.CAH benefits from strong demand in injectable GLP-1s, driving higher distribution volumes across pharma.Oral GLP-1 adoption may grow over time, supporting sustained top-line gains despite modest profit impact.Cardinal Health (CAH) is clearly benefiting from the rapid adoption of GLP-1 therapies, though the impact remains more pronounced on revenues than profitability. In the second quarter of f ...

Mark Romaine, Chief Operating Officer of Global Partners LP (GLP 3.81%), reported the direct sale of 15,611 common units across multiple transactions between March 16 and March 18, 2026, as disclosed in a SEC Form 4 filing. Transaction summaryMetricValueUnits sold (direct)15,611Transaction value~$740,000Post-transaction units (direct)146,874Post-transaction value (direct ownership)~$7.04 millionTransaction value based on SEC Form 4 weighted average purchase price ($47.38); post-transaction value is based on ...

Core Viewpoint - The innovation of semaglutide for diabetes and obesity is considered a game-changing moment in weight management globally, including in India [1] Group 1: Product Launch and Market Dynamics - Semaglutide was launched as an injectable product less than a year ago, and the company is now facing generic competition, which is seen as a necessary change [2] - The company reduced the pricing of semaglutide by 37% to cater to the patient population in India, reflecting a patient-centric approach [3] - The access to these medications has significantly increased in India over the past four to five months due to the price reduction [4] Group 2: Manufacturing and Quality Assurance - The company emphasizes the quality of its products, including the RNA and RDNA-based manufacturing process, which is imported from Denmark [4] - The company has world-class fill and packaging facilities, ensuring that the science and technology behind the product justify the pricing after the reduction [5] Group 3: Distribution and Accessibility - Partnerships with companies like Mure and Abbott are aimed at expanding the reach of semaglutide in tier two and tier three cities in India [6][7] - The increasing number of endocrinologists and internal medicine doctors in these cities is enhancing access to diabetes and obesity treatments [8] - There is a notable shift in the prescription of insulin from urban to rural areas, indicating a potential similar trend for GLP-1 medications like semaglutide [9]

Key Takeaways LLY shares fell 5.9% after an HSBC downgrade citing U.S. pricing pressure and rising obesity-drug competition.HSBC warned that pricing pressure and affordability push could reshape competition in the obesity drug market.Continued availability of compounded tirzepatide in the U.S. could divert demand from LLY's branded drugs.Eli Lilly (LLY) remains a dominant player in the global obesity market, with much of its recent growth driven by itsblockbuster tirzepatide (GLP-1) injections, Mounjaro for ...

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA- 1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control Accessibility StatementSkip Navigation About MetaVia MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Meta ...

Group 1 - Structure Therapeutics (GPCR) released new topline data from the Phase 2 ACCESS II trial, resulting in a stock increase of approximately 5% [1] - The initial data from the trial is viewed positively, supporting a bullish outlook for the company [1] Group 2 - The focus is on identifying promising biotechnology companies that innovate through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The analysis emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]

Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth - 24/7 Wall St. S&P 5006,709.70 +1.30% Dow Jones47,015.60 +1.14% Nasdaq 10024,702.20 +1.54% Russell 20002,516.79 +1.73% FTSE 10010,361.60 +1.20% Nikkei 22554,589.50 +2.38% Live Nasdaq Composite: Tech Leads, Oil Eases With AI's Next Chapter in Focus Investing Follow 24/7 Wall St. on Google This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. How to Add Us to Go ...

Core Insights - Eli Lilly (LLY) is a leading player in the global obesity market, primarily generating revenue from its GLP-1 medications, Mounjaro and Zepbound, which account for over 50% of total revenues [2][11] - In 2025, combined sales of Mounjaro and Zepbound reached $36.5 billion, representing approximately 56% of Eli Lilly's total revenues, with strong growth expected to continue into 2026 [3][11] - The company is preparing to launch orforglipron, an oral GLP-1 therapy, in the U.S. in Q2 2026, which could attract patients who prefer non-injection options [4][11] Market Expansion and Policy Developments - Eli Lilly aims to expand access to its obesity and diabetes drugs, supported by recent policy changes, including the U.S. government's CMMI BALANCE Model, which will enhance Medicare coverage for GLP-1 therapies starting in 2027 [5][6] - The Medicare GLP-1 Bridge Model will launch in July 2026, potentially facilitating earlier adoption of Lilly's obesity treatments [6] - Expanded Medicare coverage and lower patient costs are expected to significantly boost demand for Lilly's obesity drugs, despite potential reductions in Medicaid coverage in some states [7] Competitive Landscape - Eli Lilly and Novo Nordisk (NVO) are the dominant players in the obesity market, with both companies competing through their GLP-1 therapies [9] - Novo Nordisk has recently launched an oral version of its GLP-1 drug Wegovy, which could broaden patient access and intensify competition in the market [10] Stock Performance and Valuation - Eli Lilly's stock has increased by 32.4% over the past six months, outperforming the industry average growth of 20.4% [13] - The company's shares currently trade at a price/earnings ratio of 28.03, which is higher than the industry average of 17.99, but below its five-year mean of 34.57 [16] - Earnings estimates for 2026 have improved from $33.11 to $34.16 per share, while 2027 estimates have risen from $41.48 to $41.90 per share [18]

Core Insights - Novo Nordisk (NVO) has partnered with telehealth platform Hims & Hers Health (HIMS) to enhance access to its FDA-approved semaglutide medications in the U.S. This partnership allows HIMS to offer Ozempic and Wegovy at self-pay prices, potentially increasing access to NVO's GLP-1 therapies [2][4] Partnership Details - The partnership enables HIMS to provide various approved doses and formulations through telehealth consultations and pharmacy networks, which may broaden the reach of NVO's branded therapies that have shown cardiovascular benefits [2] - HIMS will cease advertising compounded GLP-1 products and will transition existing patients to FDA-approved alternatives when appropriate. In exchange, Novo Nordisk will drop its patent infringement lawsuit against HIMS while retaining the right to refile [5] Market Reaction - The announcement of the partnership led to a significant increase in HIMS shares, while NVO shares also saw a modest rise as investors perceived the deal as a strategic move to direct patients towards FDA-approved products [3][4] Competitive Landscape - The partnership may strengthen NVO's position against Eli Lilly (LLY), which markets competing GLP-1 therapies. LLY's products have been eroding NVO's market share, and the competition is expected to intensify with LLY's oral GLP-1 candidate under FDA review [6] Regulatory Concerns - NVO's stock price gains were partially offset by the disclosure of a warning letter from the FDA regarding post-marketing safety reporting processes at its New Jersey facility. However, the company stated that this issue does not affect the quality or safety of its medicines and does not expect it to impact production or financial guidance for 2026 [7][8] Financial Performance - In 2025, LLY's GLP-1 drugs generated combined sales of $36.5 billion, accounting for approximately 56% of the company's total revenues, highlighting the competitive pressure in the obesity and diabetes treatment markets [10] - Over the past six months, NVO shares have declined by 29.4%, underperforming the industry growth of 20.8% and the S&P 500 [12] Valuation Metrics - NVO shares are currently trading at a price/earnings ratio of 11.63, which is lower than the industry average of 18.06 and significantly below its five-year mean of 29.25 [16] - Earnings estimates for 2026 have decreased from $3.54 to $3.35 per share, and for 2027, estimates have dropped from $3.75 to $3.26 [18]